Chronic cannabinoid exposure reduces phencyclidine-induced schizophrenia-like positive symptoms in adult rats
- 623 Downloads
Chronic cannabis use can induce psychotic states that resemble schizophrenia. Yet, schizophrenic patients often smoke cannabis as a form of self-medication to counter the aversive symptoms of schizophrenia. We recently demonstrated an ameliorating effect of cannabinoid self-administration (SA) on negative and cognitive schizophrenia-like symptoms induced experimentally by the non-competitive N-methyl-d-aspartate receptor antagonist phencyclidine (PCP). Whether cannabinoid SA alleviates or exacerbates schizophrenia-like positive symptoms is still unclear.
This follow-up study aimed to evaluate the effect of self-administered cannabinoid on PCP-induced schizotypic positive symptoms in adult rats.
Male rats were trained to self-administer either the cannabinoid CB1 receptor agonist WIN 55,212-2 (WIN; 12.5 μg/kg/infusion) or its vehicle (Veh) intravenously. The effects of acute and chronic intermittent intraperitoneal administration of PCP (2.5 mg/kg) on motor parameters were then tested in Veh-SA and WIN-SA.
Cannabinoid SA significantly attenuated the psychotomimetic effects of PCP exposure observed in control rats. Following acute PCP administration, WIN-SA animals displayed more frequent rearing and lower anxiety-like profile than Veh-SA rats. WIN-SA rats also exhibited lower behavioural sensitisation to chronic PCP treatment as demonstrated by reduced hyperlocomotion in response to an acute PCP challenge. In addition, parallel experiments performed in experimenter-administered rats that received WIN at comparable SA doses confirmed the ameliorating effects of cannabinoid exposure on PCP-induced schizotypic behaviours, indicating that motivational effects were not responsible for the ameliorative effects of cannabinoids.
Our results indicate that cannabis may exert protective effects on positive schizotypic symptoms in adult animals such as hypermotility and anxiety state.
KeywordsCannabinoids PCP Schizophrenia Self-administration Psychosis Locomotor activity Anxiety Comorbidity Abuse
This study was supported by funds (PRIN 2005) from the Italian Ministry of University and Scientific Research (MIUR). The authors are grateful to Dr. Barbara Tuveri for animal care and technical assistance.
Conflict of interest
- Campiani G, Nacci V, Bechelli S, Ciani SM, Garofalo A, Fiorini I, Wikström H, de Boer P, Liao Y, Tepper PG, Cagnotto A, Mennini T (1998) New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure. J Med Chem 41:3763–3772PubMedCrossRefGoogle Scholar
- Degenhardt L, Tennant C, Gilmour S, Schofield D, Nash L, Hall W, McKay D (2007) The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10-month prospective study. Psychol Med 37:927–934PubMedCrossRefGoogle Scholar
- Long LE, Chesworth R, Huang XF, McGregor IS, Arnold JC, Karl T (2009) A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. Int J Neuropsychopharmacol 29:1–16Google Scholar
- Pryor GT, Husain S, Larse F, McKenzie CE, Carrr JD, Braude MC (1977) Interactions between delta9-tetrahydrocannabinol and phencyclidine hydrochloride in rats. Pharmacol Biochem Behav 6:126–136Google Scholar
- Viveros MP, Marco EM, Llorente R, López-Gallardo M (2007) Endocannabinoid system and synaptic plasticity: implications for emotional responses. Neural Plast 52908Google Scholar